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ABSTRACT
The fields of regenerative medicine and cellular therapy have been the subject of tremendous hype and hope. 
In particular, the perceived usage of somatic cells like mesenchymal stromal cells (MSCs) has captured the 
imagination of many. MSCs are a rare population of cells found in multiple regions within the body that can 
be readily expanded ex vivo and utilized clinically. Originally, it was hypothesized that transplantation of 
MSCs to sites of injury would lead to de novo tissue-specific differentiation and thereby replace damaged 
tissue. Now, it is generally agreed that MSC home to sites of injury and direct positive remodeling via the 
secretion of paracrine factors. Consequently, their clinical utilization has largely revolved around their abilities 
to promote neovascularization for ischemic disorders and modulate overly exuberant inflammatory responses 
for autoimmune and alloimmune conditions. One of the major issues surrounding the development of somatic 
cell therapies like MSCs is that despite evoking a positive response, long-term engraftment and persistence of 
these cells is rare. Consequently, very large cell doses need be administered for raising production, delivery, 
and efficacy issues. In this review, we will outline the field of MSC in the context of ischemia and discuss 
causes for their lack of persistence. In addition, some of the methodologies be used to enhance their therapeutic 
potential will be highlighted. 
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INTRODUCTION
Despite improved management and availability of 
conventional therapies, cardiovascular disease remains the 
leading cause of death in the Western World. Furthermore, 
as the incidence of cardiovascular disease increases, 
so increases the number of “no-option” patients who 
continue to have disabling ischemia after all conventional 
revascularization techniques have failed. Thus, development 
of new therapeutic options for these patients is a priority. 
Under development are strategies involving therapeutic 
angiogenesis, which attempt to exploit the body’s natural 
ability of to develop collateral vessels following ischemia. 
Despite promising results in animal models, many of the 
protein and gene-based strategies used for therapeutic 
angiogenesis have been clinically disappointing.[1] In 
particular, the short half-life of recombinant proteins 
and the inefficient delivery and expression of in vivo gene-
based strategies continue to be the major challenges. In 
recent years, there has been a growing enthusiasm for the 
application of cell-based therapies to repair or regenerate 
ischemic tissue. In particular stem/progenitor cells from 
the bone marrow have demonstrated regenerative and 
angiogenic properties. Conceptually, cell therapy for 
cardiovascular disease has evolved from the initial premise 
that exogenous progenitor or stem cells regenerate 
injured tissue to a broader hypothesis that cell therapy 
facilitates complementary aspects of tissue repair.[2] Such 
complementary aspects might include augmentation 
of cell survival (limited apoptosis), tissue oxygenation 
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(neovascularization), and improvement in recovery of 
cellular and tissue function (positive remodeling). 
In numerous animal models, bone-marrow-derived 
mesenchymal stromal cells (MSCs) have shown promise 
in the treatment of cardiovascular disease.[3-5] Indeed 
MSCs have intrinsic features which identify them as an 
ideal cell type for cardiovascular cellular therapy. MSCs 
possess robust angiogenic and immunomodulatory 
properties, are a natural constituent of the host-derived 
tissue ischemia response, can be obtained in relatively 
large numbers through standard clinical procedures, and 
are easily expandable in culture.[6] However, as is the case 
in all cellular therapies, low MSCs survival/engraftment 
rates post-transplantation limits their overall effectiveness 
and significantly impacts their clinical usage.[7] 
MESENCHYMAL STROMAL CELL BACKGROUND
In the 1970s, a unique population of cells was isolated from 
the bone-marrow-based on their ability to adhere to plastic 
and to support hematopoietic cell growth.[8] These cells 
have since been referred to as mesenchymal stromal cells. 
These cells account for only about 1:100,000 mononuclear 
cells in the bone marrow,[9] but decrease in frequency with 
age.[10] Since their initial isolation from the bone marrow, 
analogous cells have been successfully isolated from a 
variety of sources including adipose, placental, umbilical, 
and vascular tissue,[11] and it has been suggested that the 
natural niche of MSCs are as vascular mural cells called 
pericytes.[11] Typically, these cells are characterized by their 
multipotential capacity to differentiate into osteoblasts, 
chondrocytes, and adipocytes and by a panel of surface 
markers which distinguishes these cells from endothelial, 
hematopoietic, and monocyte like cells. MSCs are typically 
positive for CD44, CD73, CD90 (Thy-1), and CD105 
(endoglin))[9] and negative for hematopoietic (CD45, or 
lineage [Lin] markers), endothelial (CD31, von Willebrand 
factor) and macrophage (CD11b/MAC-1) markers. 
Despite being a rare population of cells, MSCs can 
be extensively expanded ex vivo making them clinical 
useful.[9] Their well-documented proangiogenic[12] and 
immunomodulatory[13] features make them attractive 
as a cellular biopharmaceutical for numerous disease 
indications. Furthermore, because naïve MSCs lack cell 
surface expression of MHC class II and costimulatory-
type molecules (i.e., CD80/CD86) MSCs are considered 
immunopriviledged[14] suggesting they can be used in a 
universal donor platform in much the same fashion as 
type “O” blood.
Since 2000 there have been more than 7000 research 
publications involving MSCs and a multitude of preclinical 
studies have explored the use of MSCs in applications as 
diverse as bone/cartilage tissue engineering, cardiovascular 
regeneration, immunomodulation, gene therapy, and neural 
regeneration. Moreover, there have been over 200 registered 
clinical trials using MSCs worldwide (http://clinicaltrials.
gov, search was performed using most known names of 
MSCs). Most of these studies targeted immune-related 
disorders (multiple sclerosis, graft versus host disease, 
Crohn’s disease), cardiovascular conditions (myocardial 
infarction, ischemia), and orthopedic reconstruction, but 
pulmonary and neurological conditions are also under 
investigation. More than any other somatic cell MSCs have 
been proposed as a game changing medical application; 
however, a lack of persistence of MSCs at their intended 
site of action is a major concern regarding their clinical 
realization. 
MECHANISM OF ACTION
In situ differentiation of MSCs
In one of the first studies to demonstrate the therapeutic 
utility of bone marrow and MSCs for cardiac indications. 
Orlic et al, suggested that once transplanted these cells 
had the potential to differentiate into both endothelial 
and myogenic cell lineages.[15] This prompted the idea that 
MSC could be used to replace damaged tissue with new 
functional myocardium. This idea was very attractive given 
the knowledge that a myocardial infarction can result in the 
loss of over 1 billion cells[16] and the potential for large scale 
clinical expansion of MSCs. However, subsequent studies 
have clearly established that in situ differentiation of MSCs 
is an exceedingly rare event[16,17] and this subtle endogenous 
differentiation cannot explain the dramatic in vivo effects of 
MSCs. Rather a growing consensus has shown that MSCs 
evoke their therapeutic effects via the secretion of soluble 
mediators. Therefore, MSC therapy for cardiovascular 
disease has evolved from the initial premise that MSCs 
could replace damaged tissue to the concept that via 
paracrine mediators MSCs facilitate complementary aspects 
of tissue repair. Such complementary aspects might include 
augmentation of tissue oxygenation (angiogenesis), cell 
survival (limited apoptosis), and improvement in recovery 
of cellular and tissue function (positive remodeling).
Therapeutic neovascularization by MSCs
One of the earliest indications that MSCs could be 
useful as therapeutic tool was the demonstration that 
MSCs could promote new blood vessel formation. 
Neovascularization is combination of vasculogenesis, 5 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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angiogenesis, intussusception, and arteriogenesis. 
Vasculogenesis is the in situ differentiation of precursor 
cells into endothelial cells, angiogenesis, on the other hand 
is the sprouting of new blood vessels from pre-existing 
vessels, while intussusception is new blood vessel formation 
by splitting off existing ones. Arteriogenesis is the rapid 
proliferation and maturation of pre-existing collateral 
arteries to accommodate increase vascular flow and is 
consider a critical process in proper neovascularization 
of ischemic tissue.[18] We have previously described that 
murine MSCs display robust neovascularization in vivo 
which occurs predominately via a host-derived angiogenic 
response,[19] while gene array and protein studies on MSCs 
have documented the release by MSCs of a wide spectrum 
of factors that are relevant to angiogenesis. These include 
factors such as VEGF, FGF, IL-6, MMPs,[12,20,21] HGF, 
and IGF.[22,23] Furthermore, MSCs secrete factors such as 
MCP-1, Angiopoietin-1, PDGF, and FGF which are critical 
for arteriogenesis.[12] The ability of MSCs to promote new 
blood vessel growth is considered to be a key component 
of their therapeutic potential in myocardial ischemia. 
Furthermore, there is developing evidence that part of 
the etiology of chronic lung disease of the newborn is due 
to vascular pruning and early studies have indicated that 
MSCs my resolve this disease by prompting new vessel   
growth.[24] Several studies have demonstrated that collecting 
the secreted factors form MSCs alone is sufficient to 
promote therapeutic angiogenesis;[12,25] however, whether 
this is this is clinically relevant remains to be seen. 
Antiapoptosis actions of  MSCs
During ischemia myocardial tissue die via one of several 
types of “programmed cell death (PCD).” At one spectrum 
is controlled PCD or apoptosis; an energy-dependent 
active process involving the sequential activation of 
proteases and other hydrolases that rapidly degrade 
cellular structures. This process occurs within an intact 
plasma membrane usually affects individual cells and 
generally does not evoke a proinflammatory response. At 
the opposite extreme is uncontrolled PCD or necrosis, 
which is considered a passive process that affects large 
fields of cells, is toxic to neighboring cells and evokes an 
inflammatory response. Whether a cell dies by controlled 
PCD or necrosis depends the nature of the death signal(s), 
the tissue/cell type and the local milieu.[26] At the center 
of the apoptotic process are two families of proteins, 
the caspases and members of the Bcl2 extended family. 
The caspases form a cascade in which initiator caspases 
(i.e., caspase-2, -8, -9, -10) are activated by lethal stimuli 
arising from the intrinsic, extrinsic pathways, then in turn 
activate a set of effector caspases (i.e., caspase-3, -6, -7). 
These effector caspases then synchronously cleave protein 
in multiple cellular compartments which result in the 
classical morphological changes of apoptosis.[27] Besides 
the caspases, apoptosis that is initiated at the mitochondria 
(intrinsic pathway) is also tightly controlled by the Bcl-2 
family by impacting cytochrome c release. Bcl-2 family 
members can be subclassified into three groups; the 
antiapoptotic multidomain members (Bcl-2, Bcl-Sl and 
Mcl-1), the pro-apoptotic multidomain members lacking 
the BH4 domain (i.e., Bax and Bak) and the pro-apoptotic 
BH3-only proteins (i.e., Bid, Bim, and Bad).[28] Following 
the activation of the executioner caspases, apoptosis 
is generally irreversible and these results in extensive 
plasma membrane blebbing, followed by karyorrhesis and 
separation of cell fragments into apoptotic bodies by a 
process called “budding.” These apoptotic bodies consist 
of cytoplasm with tightly pack organelles and can also 
contain nuclear fragments. These bodies are subsequently 
phagocytized by macrophages, parenchymal cells and 
degraded in the phagolysosome.[29] In case of ischemia 
induced myocardial cell death both apoptotic pathways are 
relevant with the intrinsic pathway predominating initially 
while the extrinsic pathway become more prominent 
once innate inflammatory mediators like neutrophils and 
macrophages have migrate into the area. MSCs have been 
shown to have a profound impact on local cell survival, 
by secreting a number or pro-survival factors which can 
counteract the proapoptotic signals induced by either the 
extrinsic or intrinsic pathway. In particular, MSCs have 
been shown to minimize myocardial apoptosis due to 
oxidative stress,[30] ischemia,[31] and cytokine exposure.[32] 
The specific secreted factors by which MSCs influence 
cardiac apoptosis vary however, the principle factors that 
MSC secrete which have been shown to impact apoptosis 
are HGF, TGF-β, VEGF, IGF-1, Sfrp2,[33] and stanniocalcin 
1.[34] These factors have the ability to bind to receptors on 
local vulnerable cells and evoke signaling pathways which 
can either promote survival or counteract pro-apoptotic 
mediators. The most prominent signaling pathways are the 
MAP-kinase, and PI3K- AKT signaling axis, however the 
SMADs and STAT signaling pathways are also associate 
with pro-survival characteristics. 
Anti-inflammatory actions of  MSCs
Because of its high metabolic rate the myocardium is 
particularly susceptible to undergoing irreversible cell 
death following ischemia. The resulting necrosis of 
cardiomyocytes, endothelial, neural and stromal cells 
elicits a vigorous inflammatory within the infarcted 
area initially composed of neutrophils and subsequently 
switching to macrophages. The extent of this inflammatory 
response will directly influence scar size and formation 
of granulation tissue.[35] A unique feature of MSCs, which 6 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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has led to their investigation in multiple conditions and 
potential use as universal donor cell is that these cell have 
clinically exploitable immune modulating properties. For 
instance, MSCs have been shown to inhibit dendritic cell 
maturation, B and T cell proliferation and differentiation, 
attenuate NK cell killing and support the generation of 
suppressive regulatory T cells.[36-38] Previously we showed 
that erythropoietin-expressing MSCs could reduce 
the neutrophil burden in the infarcted heart,[39] while 
Raffaghello et al, demonstrated that MSCs can influence 
neutrophil apoptosis.[40] This suggest that in the ischemic 
heart, MSCs can help expedite neutrophil apoptosis which 
will reduce the release of tissue damaging mediators like 
reactive oxygen species and help prevent a secondary 
wave of neutrophil recruitment. Complementarily to this, 
MSCs have the ability to recruit macrophages to sites 
of injury[41] and can then re-educate these macrophage 
to become CD206 expressing immunosuppressive cells 
that secrete high levels of IL-10.[42,43] Mechanistically, 
the immunomodulatory characteristic of MSCs are 
still being defined; however, it is clear that both soluble 
factors such as TGF-β PGE2, HLA-G5, IL1Rα, NO, 
and IDO,[44] as well as, cell contact[45] have roles to play. 
Experimentally and clinically, MSCs have been shown 
to impact alloimmune conditions such as GvHD[46,47] 
and autoimmune inflammatory bowel disease (IBD).[48] 
Furthermore, experimental evidence suggests MSCs can 
positively modulate inflammatory conditions associated 
with ischemia.[49] Indeed Chen et al, recently demonstrated 
that intramyocardial injection of MSC shortly after 
coronary ligation, decreased the proinflammatory/anti-
inflammatory cytokine ratio in the myocardium early 
after MI and this reduction was associated with less scar 
formation and improved cardiac function.[50] Whether the 
anti-inflammatory actions of MSCs in the cardiac setting 
are a result of direct modulation of inflammatory cells or 
secondary to a reduction in myocardial cell death remains 
to be established. 
Augmenting endogenous repair
Originally the adult myocardium was considered a 
non-regenerative tissue, meaning local cells could not 
coaxed to replace or replenish dead or damaged tissue. 
The paradigm of the heart being a postmitotic organ, 
however, was challenged by the discovery of cardiac 
progenitor cells (CPCs), which are clustered in specialized 
microenvironments (niches) throughout the myocardium 
in the adult heart. CPC populations are classified into 
different subtypes, based on their surface markers: Sca1+, 
Isl1+, and c-kit+.[51] CPC appear to migrate and accumulate 
within ischemia and scarred myocardium and can evoke 
cardiac regeneration.[52] A significant study by Dawn et 
al,[53] showed that intravascular administration of CPCs 
migrate to the myocardium, promote myocyte regeneration, 
form new coronary vasculature, and reduce infarct size. A 
recent study also revealed that the engrafted CPCs not only 
enhanced function and reduced ventricular dilation, but 
also replaced almost 42% of the scar with newly formed 
myocardium.[54] Despite these advantages, the therapeutic 
use of CPCs becomes complicated, owing to the difficulties 
in acquiring myocardial samples from patients and their 
expansion in quantities of therapeutic significance.[55] 
Therefore, local injection of factors to incite the resident 
CPCs has been offered as an effective approach to mediate 
myocardial regeneration. MSCs have been shown to secrete 
a number of chemotactic factors which can contribute to 
the activation and migration of CSC toward areas of injury. 
Indeed MSCs have been shown to secrete: CCL2, CCL3, 
CCL4, CCL5, CX3CL1, CXCL5, CXCL8, CXCL10, and 
CXCL12.[56-59] Recently, it was shown that the paracrine 
effects of MSCs can be used as an indirect approach to 
activate the resident endogenous CPCs.[60] Furthermore, 
Unzek et al, demonstrated the importance of MSC CXCL12 
expression by showing the transplantation of CXCL12 
overexpression MSCs at the time of acute MI leads to 
the recruitment of endogenous cardiac myosin stem cells 
that are capable of depolarizing and thus likely contribute 
to increased contractile function following MSCs cell 
transplantation.[61] 
Increased chamber mass a placebo effect of  cellular therapy
Certainly, the paracrine actions are critical components 
of why MSCs are therapeutic, however it should not 
be forgotten that in situations where cells are directly 
injected into the myocardium increased cell mass may 
alone increase the stiffness of an ischemic area and thereby 
decrease wall stress. The merit of this idea is supported 
that fact that some very different cell types produce very 
similar effects when injected into the myocardium. Indeed 
in rodent cardiac ischemia models which frequently 
display thin fibrous aneurysms following ischemia any 
increase in chamber mass will show a particularly large 
functional effect. Therefore, one should be cognizant 
when considering the translation of a cellular therapy from 
murine models that any increase in wall mass will likely 
show functional benefits over the short term; however, 
long-term benefit is far less likely. 
Clinical use of  MSCs for ischemia
Since the early 2000s numerous clinical trials have 
demonstrated the feasibility, and safety of delivering bone 
marrow cells and MSCs to patients with recent myocardial 
infarctions.[62] For those patients receiving unfractionated 
autologous bone marrow cells following acute MI 7 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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significant improvements in left ventricular ejection fraction 
have been reported as have reductions in infarct size and 
left ventricular systolic volume.[63-65] Unfortunately, these 
changes are modest at best and do not seem to persist long 
term.[66] Low numbers of progenitor and stem cells found 
within the unfractionated bone marrow is considered a 
primary cause for these modest effects and has prompted 
the investigation of more homogeneous cell preparation 
to determine which cell type(s) is most beneficial for 
cardiovascular disease. In 2004, Chen et al, reported a 
small randomized trial in which infusion of autologous 
MSCs resulted in a significant and sustained improvement 
in cardiac function in patients following acute myocardial 
infarction.[6] The 18% improvement in LEVF generated 
tremendous excitement and helped foster multiple clinical 
trials by both academic and private entities. Indeed, a 
multitude of companies have been formed around the 
potential of MSC-like cells for tissue repair. Recently, 
Osiris reported positive phase I data for their allogeneic 
MSC product in reperfused MI patients,[67] while Cardio3 
BioScience reported an impressive 18% improvement in 
LVEF in acute MI patients receiving autologous MSCs 
expanded using their proprietary cardiopoiesis platform 
(http://www.c3bs.com/). At present, there are over 25 
registered clinical trials investigating the used of MSCs 
for treatment of cardiac disease, however many of these 
studies are still considered early efficacy and safety studies 
and the reporting of data has been surprisingly scarce. 
Therefore, until there is convincing data from a large 
multicentered clinical trial, MSCs as therapy for cardiac 
disease must be still considered experimental. Indeed, 
there are still many questions regarding how and when to 
deliver the cells at what dosage and whether allogeneic cells 
are as efficacious as autologous MSCs. In the following 
sections, we will outline some of the issues surrounding 
the development of MSCs for cardiac disease. 
Delivery of MSC cells
One of the major issues plaguing the clinical application 
of MSCs for cardiac indications is the extremely low 
retention rates of cells post-transplantation. MSCs have 
been delivered to the heart via different routes with varying 
retention rates. Hou et al,[68] demonstrated MSC retention 
rates of 3%, 11%, and 3% following: intracoronary (IC), 
intramyocardial (IM), and intravenous (IV) delivery with 
long-term persistence of MSCs post-transplantation (i.e., 
>2 weeks) is generally less than 1%.[69] Consequently, very 
high cells doses need to be administered raising production, 
safety, and efficacy issues.
For cardiac delivery, MSCs can be delivered via four 
main routes: endocardial; epicardial; intracoronary, and 
via percutaneous retrograde coronary sinus infusion. A 
variety of injection catheters have been specially designed 
to augment cardiac retention of MSCs, however, both 
intravenous and intramyocardial delivery of MSCs are 
plagued by a variety of issues. When injected intravenously 
MSCs must home to damaged tissue to evoke a therapeutic 
response. Endogenous and exogenously administered 
hematopoietic stem cells are known to be recruited from 
the blood vessels to the surrounding tissue in a process 
similar to that of leukocytes.[70] This is a sequential process 
that involves selectins, chemokines, integrins, and other 
adhesion molecules.[71,72] Although far less efficient than 
leukocytes or HSCs, data suggests that MSCs[73] can also be 
selectively recruited in the body. It is theorized that MSCs 
roll, tether, and undergo extravasation similar to leukocytes 
and HSCs; however, distinct adhesion molecule expression 
patterns likely explain the low efficiency of recruitment of 
specific MSC populations. Besides active recruitment of 
MSCs there is also the theory that exogenously administered 
cells can be passively entrapped at a site of injury and 
subsequently extravasate. The passive entrapment theory 
is supported by the high numbers of MSCs that can be 
found in the lung[69] immediately following intravenous 
infusion and by the idea that local injury/inflammation 
can result in microvessel constriction[74] increasing passive 
entrapment at sites of injury.[73] Exactly what contribution 
active and passive recruitment play in overall recruitment 
of MSCs to the heart is unclear, however, it is clear that 
MSC homing is inefficient. 
Intracoronary infusion has been the method of choice 
for nearly all initial MSC studies with patients with ST-
segment elevation MI. Coronary transfer requires that 
target myocardium be adjacent to an angiogenically 
patent coronary artery or identifiable collateral vessel. 
The position of the catheter is determined by the extent 
of the target territory. MSC are generally infused in a 
continuous manner or a repetitive “stop-flow” method. 
The advantage of coronary MSC transfer is the ability 
to have homogenous distribution within the target area, 
however, since MSC trafficking is so inefficient many cells 
do not properly migrate to the target area. Percutaneous 
retrograde coronary sinus delivery is an alternative method 
of intravascular delivery of MSCs. The technique involves 
placement of a catheter into the coronary sinus via either 
the internal jugular or femoral vein. A single of double 
balloon is inflated, followed by infusion of MSCs for 
5−30 min at a pressure approximately 20 ml higher than 
the coronary sinus pressure. Theoretically percutaneous 
retrograde coronary sinus allows MSCs to engage the 
coronary endothelium for a longer period of time and at 8 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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a lower velocity and thus should allow better attachment 
and extravasation at the target area. 
To overcome the low efficiency of proper homing of 
intravenously delivered MSCs, investigators are increasingly 
looking to use direct tissue injection. This is particularly 
relevant for MSC therapies aimed at treating cardiac, 
neural, and orthopedic disorders. The idea of direct 
tissue injection is based on the premise that once at their 
intended site of action cells will survive and evoke positive 
tissue remodeling. Certainly, in small animal models direct 
tissue injection has shown promising results, however 
one must accept that mode of injection, dosage and 
timing are not clinically realistic. For example, in murine 
models of myocardial infarction MSCs are often injected 
via thoracotomy immediately following the ischemic 
insult at a cell dosage that can be 5−10 times higher than 
which is being evaluated clinically. Furthermore, when put 
into practice in large animal models additional concerns 
regarding direct tissue injection become evident. These 
concerns revolve around issues such as: the immediate loss 
of cells due to wash-out and local lymphatic drainage,[75] the 
inability of transplanted cells to migrate within the tissue, 
the number of injection sites that can be performed and 
the dosage which can be administered at each injection site. 
Despite these drawbacks, several devices have been 
developed to enhance deliver MSCs to ischemic areas. For 
transendocarial intramyocardial cell delivery, BioCardia 
has designed the Helical Infusion catheter with a small, 
hollow distal corkscrew needle, which can be rotated 
into cardiac tissue to provide active fixation during cell 
delivery, while the Myostar Injection Catheter (Biosense 
Webster) is designed with deflectable tip and retractable 
injection needle whose depth is adjustable from 2−10 
mm. Both these injection systems have proven themselves 
efficacious in animal models,[76] however, proper injection 
of cells require sophisticated intraventricular guidance 
systems (i.e., 2D fluoroscopic or 3D NOGA mapping) to 
identify and injection sites. Alternatively, several catheter 
systems are being developed for intracoronary delivery 
of cells. Specifically, new devices are being tested for the 
coronary perivascular (adventitial) delivery of MSCs with 
microneedle injection balloon catheters. Mercator has 
developed the Cricket™ and Bullfrog® Microinfusion 
catheters which are the first catheter-guided systems 
designed to inject MSCs through blood vessel walls into 
deep tissues. Microinfusion catheters are comprised of a 
catheter tipped with a balloon-sheathed microneedle, and 
are guided and inflated in a manner similar to an angioplasty 
catheter. When the desired injection site is reached, the 
balloon is inflated with saline, securing the system for 
injection and sliding the microneedle through the vessel 
wall. The closed balloon provides a protective covering for a 
tiny injection needle as it is guided through the vasculature. 
In a swine model of myocardial infarction mircoinfusion 
catheter delivery of MSCs was capable of producing a 
therapeutic effect,[32] however, whether it is superior to 
other delivery methods remains to be established.
Unlike, transendocardial, transvascular or even 
intracoronary delivery of MSCs, epicardial delivery of 
MSCs does not require any specialized imaging equipment 
to determine injection location. Epicardial delivery of 
MSCs is considered the most reliable method due to the 
high accessibility of the ischemic area due to surgical 
exposure. Prior to surgery the areas of injection are initially 
identified by echocardiography or MRI and then by direct 
visualization. Direct visualization allows for easy avoidance 
of injection into the ventricular chamber or epicardial 
arteries. Despite these benefits, epicardially delivery does 
necessitate an invasive procedure which many patients are 
too fragile to undergo or their physicians are reluctant to 
perform. Furthermore, epicardial delivery is associated 
with significant leakage of cells from their injection 
sites decreasing the actual amount of material delivered. 
Consequently, epicardial delivery has not been developed 
to the same extent as transendocardial, transvascular, or 
intracoronary delivery approaches.
Autologous versus allogeneic
One of the most attractive aspects of MSCs for 
cardiovascular disease is the concept that MSCs can be 
used as “off the shelf” universal donors. Indeed the 
business model for numerous cellular therapy companies 
is based on the idea that a small number of donors can 
be used to generate thousands of MSC cell doses, which 
can then be stored cryogenically and shipped as needed. 
MSCs are widely described as being MHC I+, MHC II- 
and are considered non-immunogenic due to their lack 
of expression of costimulatory molecules (i.e., CD40-, 
CD80-, and CD86-).[77] Despite this enthusiasm, and the 
in vitro data that MSCs are immune privileged there several 
reports have demonstrated that, although better tolerated 
that most cells, MSCs evoke an immune response in vivo. 
In previous work from our laboratory, Eliopoulos et al, 
demonstrated that class I and class II MHC-mismatched 
MSCs elicit a robust and specific cellular immune response 
in immunocompetent allogeneic hosts consisting of CD8+, 
NKT, and NK cells.[78] Consistent with this idea Poncelet 
et al, demonstrated that although weaker that allogeneic 
PBMCs, allogeneic MSCs injected both subcutaneously and 
intramyocardially elicited a complete immune response (i.e., 9 Journal of Cardiovascular Disease Research Vol. 2 / No 1
Copland.: MSCs for cardiovascular disease
cellular and humoral).[79] There is also mounting evidence 
that upon transplantation the environment where MSCs 
are transplanted will influence their immunogenicity. 
Specifically, several investigators have shown that in 
the presence of INF-γ, MSCs not only increase MHC 
class I expression, but can also upregulate MHC class II 
molecules and begin to act as antigen presenting cells.[80,81] 
Furthermore, data from our laboratory clearly shows that 
in response to IFN-γ, MSCs not only acquire MHC class II 
expression, but can also increase co-stimulatory molecular 
expression.[82] This concept of a post-transplantation 
increase in immunogeneicity of allogeneic MSCs within 
the heart was further demonstrated by Huang et al, when 
they showed that the acquisition of myogenic, endothelial, 
or smooth muscle characteristics by MSCs leads to an 
increase in their MHC class II expression. Their work also 
showed that the therapeutic benefit in the myocardium 
upon transplantation of allogeneic MSCs is short-lived 
in comparison to that of syngeneic/autologous cells.[83] 
Therefore, MSCs may be considered hypoimmune in their 
naïve state, but once transplanted in vivo this state is unlikely 
to persist. Hence, the potential of allogeneic MSCs to 
evoke long-lasting functional improvement is questionable 
as these cells can be actively targeted and removed by the 
host’s innate and adaptive immune systems. 
Cell death post-transplantation
Cell death of transplanted cells is considered a primary 
limiting factor in the overall effectiveness of somatic stem 
cell therapies like MSCs. Cell death post-transplantation can 
be acute or chronic and is influenced by the local milieu 
in terms of inflammatory status, cell adhesive cues and 
nutrient availability. These factors determine whether cells 
survive or undergo controlled anti-inflammatory cell death 
like apoptosis or proinflammatory death like necrosis. In 
addition, how cells are view by the host’s immune system 
will determine whether an innate or adaptive immune 
response is evoked. At the center of MSC cell death post-
transplantation is a specialized form of apoptosis called 
Anoikis. Anoikis is a Greek word meaning “homelessness” 
and refers to the process of apoptosis induced by loss 
of or inappropriate cell adhesion.[84] The role of matrix/
attachment integrity in relation to cell survival was first 
described by Meredith et al[85] and has since been shown 
to be the amalgamation of signals from multiple adhesion 
cues which determines whether a cell will survive or not. 
Anoikis is considered to be one of the main impediments 
to cellular healing process and in the context of somatic 
cell transplant is relevant in both the acute and chronic 
settings. The absence of adhesion and/or spreading can 
be considered the main cause of poor cell survival in 
somatic cell transplantation[86] and is well documented 
as a confounding factors in cell transplantation for the 
treatment of cardiac conditions.[87,88] Anoikis can be 
influenced by the prevention/disruption of cell attachment, 
the actions of proteases and inflammatory mediators, as 
well as, reactive oxygen species. In the acute setting whether 
transplanted somatic cells will survive depends on their 
ability to successfully attach to the extracellular matrix or 
cells of the local environment, while in chronic setting 
transplanted cell must resist detachment factors. 
Enhancing the therapeutic effect of  MSCs in cardiovascular disease
Numerous platforms have been developed to enhance 
the therapeutic potential of MSC in the setting of 
cardiovascular disease and can be broadly stratified into 
three major platforms: Genetic engineering, ex vivo priming, 
and augmented survival. Many investigators see an obvious 
enhancement to the use of MSC cellular therapy is to 
genetically engineer these same cells to synthesize factors 
which they do not normally produce to create a better 
“therapeutic bullet.” Probably the best known example 
of this is the overexpression of AKT in MSCs. In 2003 
Victor Dzau’s group at Duke demonstrated that MSCs 
overexpressing AKT had a significant survival advantage 
over unmodified MSC when directly injected into the heart 
of mice postmyocardial infarction. This result has since 
been shown to be reproducible in a large animal model of 
myocardial ischemia.[89] Other genetic means to enhance 
the therapeutic effect of MSCs in the cardiovascular 
setting include the overexpression of; VEGF,[30] eNOS,[90] 
HGF,[31] BCL-2,[91] heme-oxygenase-1,[92,93] Integrin-linked 
kinase,[94] angiopoietin-1,[95] PI3K-C2a,[96] GATA-4,[97] 
SDF-1,[98] CCR1,[99] CXCR1/CXCR2,[100] CXCR4,[101] and 
Cx43.[102] Our group has also demonstrated that MSCs 
can be retrovirally engineered to secrete high levels of 
Epo allows for a more robust host-derived angiogenic 
response, enhanced MSC survival, better preserves 
myocardial contractility in a murine model of MI and can 
reduce neutrophilic cellular infiltration.[39] Clearly all these 
techniques are of scientific interest; however, in almost 
all cases modulating intracellular signaling will result in 
additional regulatory hurdles and concerns regarding 
malignant transformation making their clinical translation 
arduous. 
Expansion and cell-infusion represents two areas where ex 
vivo priming has been applied and shown promising results. 
For instance changing the oxygen environment from 
normoxic to hypoxic during ex vivo expansion of MSCs 
has been shown to not only enhance the survival of the 
cells post-transplantation,[103,104] but also positively influence 
their secretion of pro-regenerative factors,[103,105,106] and 10 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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tissue homing capabilities.[107,108] Alternatively removing 
of fetal bovine serum (FBS) or other xenoantigens from 
the culture conditions, and preconditioning cells to their 
intended site of action by either nutrient deprivation[109,110] 
or by cytokine stimulation[111] have also shown promise. 
Postexpansion, there are several areas where ex vivo priming 
is possible. In particular, the vehicle fluid in which the 
cells are delivered can be readily manipulated and could 
have a major impact on cell survival. Currently, MSCs 
are injected in either phosphate buffered solution (PBS) 
or serum-free culture media, or clinically acceptable 
solutions like plasmalyte. None of these solutions has been 
optimized for cell survival and certainly were not designed 
to enhance cell adhesion or metabolic activity. Therefore, 
it is not surprising that several studies have shown that 
by simply supplementing injection solutions with factors 
such as: zinc,[112] diazoxide,[113] lysophosphatidic acid,[114] 
or erythropoietin[115-117] can improved MSC cell survival 
in vivo. Conversely, we identified PAI-1 secretion by MSC 
themselves or from cells in the local microenvironment as a 
negative influencer of MSC survival.[118] Mechanistically, we 
hypothesized that since PAI-1 prevents the conversion of 
plasminogen to plasmin, local PAI-1 levels would abrogate 
the release of local survival factors and thereby promote 
MSC death upon transplantation. However, what we 
found was the PAI-1 actually acts as an antiadhesive factor 
and in an ischemic environment this detachment leads to 
anoikis.[118] Thus, in addition to supplementing injection 
solution with prosurvival protein and metabolites, blocking 
antibodies or small molecule antagonists could be added to 
further augment the initial attachment and survival MSCs 
when being transplanted into hostile environments such 
as the ischemic myocardium.
In the previous paragraph, we eluded to the manipulation 
of adhesive cues to enhance the therapeutic potential of 
MSCs in cardiovascular disease. Based on the idea that cell 
attachment is the key to their survival post-transplantation, 
researchers have also employed numerous biomaterial 
and scaffolds to promote the survival of transplanted 
cells. Exemplifying this concept was the discovery that 
in pancreatic islet cell the transplantation of single cells 
was usually unsuccessful, however cell survival rate was 
significantly higher when donor cells were isolated along 
with adjacent matrix which protects the cells from acute 
Anoikis.[119] In the case of MSCs, cells have been seeded 
onto decellularized/devitalized tissue constructs,[120] 
been combined with a variety of hydro/thermogels and 
scaffolds[121] and cultured as detachable sheets to act as a 
cellular patches.[122]. All these methods have to some degree 
proven themselves superior to just administering MSCs 
as single cell solution; however, whether many of these 
constructs or designs are clinically translatable is debatable. 
SUMMARY
Despite improved management and availability of 
conventional therapies, cardiovascular disease remains the 
leading cause of death in the Western world. Furthermore, 
as the incidence of cardiovascular disease increases, 
so increases the number of “no-option” patients who 
continue to have disabling ischemia after all conventional 
revascularization techniques have failed. Thus development 
of new therapeutic options for these patients is a priority. 
Somatic cellular therapies like MSCs have garnered a 
tremendous amount of excitement as game changing 
therapies for myocardial regeneration. However, to date 
their widespread usage remains unrealized. Understanding 
the proregenerative mechanism of MSCs has been 
hampered by lack of persistence at their intended site of 
action. Consequently, determining therapeutic threshold, 
delivery methods and timing of delivery continues to 
confound investigators. Cell death of transplanted cells 
is considered a primary limiting factor in the overall 
effectiveness of somatic stem cell therapies like MSCs. 
Currently, there is a concerted effort to develop means to 
enhance the therapeutic potential, and survival of MSCs in 
cardiovascular disease and these represents novel second 
generation platform for the development of cell-based 
therapeutics. Ultimately, investigators will have to weigh 
the perceived efficacy of enhancement strategies with the 
potential risk of adverse events when determine clinical 
translation feasibility. 
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